January 7, 2019 08:14 AM EST
R&D

Al­ler­gan joins the great bio­phar­ma R&D mi­gra­tion to Cam­bridge

John Carroll

Editor & Founder

Dublin-based Al­ler­gan $AGN is open­ing up an R&D shop in Cam­bridge, MA, look­ing for a clear win­dow in­to the kind of sci­en­tif­ic in­no­va­tion in the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

A service from the Financial Times